A clinically significant interaction between voriconazole and rifapentine: a case report and review of evidence
Abstract
We present a case of concurrent pulmonary aspergillosis and tuberculosis in a 53-year-old male, treated with voriconazole and rifapentine. In this case, co-administration with rifapentine resulted in a markedly lower voriconazole trough concentration (0.4 μg/mL on day 7) compared to that without it (4.3 μg/mL on day 25), reflecting a 90.7% reduction. After rifapentine was discontinued and the voriconazole dose was increased to 300 mg q12h intravenously (day 8), the trough concentration remained at 0.4 μg/mL two days later (day 10). Subsequently, it increased to 3.0 μg/mL by day 14 (6 days post-adjustment) and further rose to 10.8 μg/mL by day 18 (10 days post-adjustment), exceeding the therapeutic range. The results demonstrated a significant decrease in voriconazole levels during combination therapy, an effect that persisted for over one week after rifapentine was discontinued. This case illustrates that increasing the voriconazole dose immediately after rifapentine cessation is not advisable to counteract this interaction. Furthermore, therapeutic drug monitoring should be continued even after target trough levels are attained, as the waning enzyme-induction effect may subsequently lead to supra-therapeutic exposure and potential toxicity.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.